RANDOMIZED PHASE II TRIAL OF SHORT-COURSE ANDROGEN DEPRIVATION THERAPY +/- AVASTIN FOR PSA RECURRENCE OF PROSTATE CANCER AFTER DEFINITIVE LOCAL THERAPY. (Dana Farber 08-190).

Trial Profile

RANDOMIZED PHASE II TRIAL OF SHORT-COURSE ANDROGEN DEPRIVATION THERAPY +/- AVASTIN FOR PSA RECURRENCE OF PROSTATE CANCER AFTER DEFINITIVE LOCAL THERAPY. (Dana Farber 08-190).

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Bicalutamide; Goserelin; Leuprorelin
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top